European Alliance for Personalised Medicine

European Alliance for Personalised Medicine
Name	European Alliance for Personalised Medicine
Formation	2012
Type	Non-profit
Headquarters	Brussels
Leader title	President

European Alliance for Personalised Medicine is a Brussels-based non-profit advocacy association founded to promote Personalised medicine initiatives across the European Union, the Council of Europe, and associated countries. The organisation engages with actors such as the European Commission, the European Parliament, the World Health Organization, and national agencies to align policy, research, and clinical practice in areas including genomics, biomarkers, and health technology assessment. It convenes stakeholders from the private sector, public institutions, and patient groups including representatives linked to Pfizer, Roche, Novartis, GlaxoSmithKline, and patient organisations similar to European Patients' Forum.

History

The initiative was launched amid growing interest following milestones such as the Human Genome Project, the establishment of the European Medicines Agency, and the publication of strategic frameworks by the European Commission on Horizon 2020 and later Horizon Europe. Early engagement included collaborations with research networks like European Research Council grantees and infrastructure projects tied to ELIXIR and BBMRI-ERIC. Founders drew expertise from academic centres including University College London, Karolinska Institutet, and Université Paris Cité, and industry partners such as AstraZeneca and Sanofi. Over time the organisation responded to policy shifts provoked by events like the adoption of the General Data Protection Regulation and public health crises that involved agencies such as the European Centre for Disease Prevention and Control.

Mission and Objectives

The stated mission aligns with high-level initiatives championed by entities such as the European Commission and the Organisation for Economic Co-operation and Development to integrate personalised approaches into routine care. Objectives reference priorities promoted by the European Institute of Innovation and Technology and aim to support translational science exemplified by ClinicalTrials.gov registries and translational networks like European Molecular Biology Laboratory. Core goals include accelerating access to sequencing technologies endorsed by groups like the Global Alliance for Genomics and Health, improving regulatory pathways coordinated with the European Medicines Agency, and fostering data-sharing frameworks compatible with the Committee on Bioethics of the Council of Europe.

Governance and Membership

Governance structures reflect multistakeholder models similar to boards of World Health Organization collaborating centres, with advisory input from representatives affiliated with institutions such as Imperial College London, Max Planck Society, and industry members like Bayer. Membership spans a spectrum of organisations including academic consortia, patient advocacy groups akin to European Cancer Patient Coalition, diagnostic companies paralleling Illumina, and policy bodies resembling Health Technology Assessment International. Leadership roles have attracted professionals who previously served within European Commission cabinets, national ministries such as Ministry of Health (France), and research funders like Wellcome Trust.

Key Activities and Programs

Programs mirror initiatives run by networks such as Innovative Medicines Initiative and include conferences, position papers, and pilot projects integrating diagnostics from providers comparable to Thermo Fisher Scientific. Activities have included workshops bringing together stakeholders from European Parliament committees, capacity-building efforts modeled on European School of Oncology training, and collaborative pilots with biobanks associated with BBMRI-ERIC. The organisation publishes guidance documents on topics aligned with outputs from European Reference Networks and hosts forums similar to sessions at European Society of Human Genetics congresses.

Policy and Advocacy

Advocacy targets regulatory frameworks shaped by actors like the European Chemicals Agency and legislative processes within the European Parliament. Policy positions address harmonisation of reimbursement pathways influenced by national agencies such as National Institute for Health and Care Excellence and Haute Autorité de Santé, as well as data governance interoperable with standards from ISO and initiatives from the Global Alliance for Genomics and Health. The alliance engages in stakeholder consultations related to major directives and regulations, echoing dialogues seen in debates around the In Vitro Diagnostic Regulation and cross-border health care rules linked to the Cross-Border Healthcare Directive.

Collaborations and Partnerships

Partnerships have been established with research funders and consortia similar to European Molecular Biology Organization, patient networks like Rare Diseases Europe, and industry consortia resembling Transatlantic Consumer Dialogue. Collaborative projects include joint ventures with infrastructures comparable to ELIXIR and legal-ethical exchanges drawing on expertise from bodies such as the European Data Protection Supervisor and the Committee on Bioethics of the Council of Europe. The alliance has engaged in memoranda and joint events with tertiary institutions analogous to University of Oxford and corporate partners parallel to Johnson & Johnson.

Impact and Criticism

Supporters credit the organisation with influencing policy debates in forums like European Parliament committees and informing guidance used by agencies such as the European Medicines Agency and national health technology assessors. Outputs have reportedly contributed to dialogues on reimbursement exemplified by cases considered by Court of Justice of the European Union jurisprudence and to piloting projects in national health systems comparable to NHS England. Critics, including academic commentators from universities like Maastricht University and civil society groups resembling Health Action International, have raised concerns about close links with pharmaceutical and diagnostics industries and potential conflicts of interest, echoing critiques encountered in discussions involving Pharmaceutical Research and Manufacturers of America and industry-funded advocacy. Debates continue regarding transparency, governance, and the balance between innovation incentives championed by bodies such as the European Patent Office and public interest protections advocated by the Council of Europe.

Category:European medical organizations